- Home
- KZIA vs LENZ Comparison
KZIA vs LENZ Comparison
Compare KZIA & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | LENZ |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.5M | 155.5M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KZIA | LENZ |
|---|---|---|
| Price | $12.48 | $5.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $19.50 | ★ $44.00 |
| AVG Volume (30 Days) | 252.2K | ★ 674.6K |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $4.54 |
| 52 Week High | $17.40 | $50.19 |
Technical Indicators
Market Signals| Indicator | KZIA | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 65.46 |
| Support Level | $11.39 | $4.59 |
| Resistance Level | $14.79 | $6.18 |
| Average True Range (ATR) | 1.22 | 0.27 |
| MACD | -0.20 | 0.14 |
| Stochastic Oscillator | 1.75 | 89.46 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.